Both in Pharmaceuticals
Atrium Therapeutics vs AN2 Therapeutics
Over the past year RNA returned −88.2% and ANTX returned +268.3%; their daily moves had a correlation of -0.02.
RNA −88.2% ANTX +268.3%Growth of $1, one year, split-adjusted
| Metric | RNA | ANTX |
|---|---|---|
| Price | $8.27 | $4.53 |
| Market cap | $141.5M | $170.9M |
| Today | +0.12% | −3.41% |
| 1 month | +1.6% | −19.4% |
| 6 months | −38.4% | −3.2% |
| Year to date | −88.5% | +297.4% |
| 1 year | — | +248.5% |
| Revenue growth (YoY) | −21.9% | — |
| Gross margin | 100.0% | — |
| Net margin | −672.0% | — |
| P/E (TTM) | — | — |
| Price / sales | 3.9× | — |
| Net cash | $263.9M | $78.4M |
| Dividend yield | — | — |
| Volatility (60d) | 65.3% | 74.5% |
| Short % of float | 22.9% | 10.0% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).